Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular CarcinomaSummary

Background & Aims: Sorafenib is a multireceptor tyrosine kinase inhibitor that can prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Although most HCC patients who receive sorafenib ultimately show disease progression, it still is unclear whether and how HCC cell...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tomomi Hashiba, Taro Yamashita, Hikari Okada, Kouki Nio, Takehiro Hayashi, Yoshiro Asahina, Tomoyuki Hayashi, Takeshi Terashima, Noriho Iida, Hajime Takatori, Tetsuro Shimakami, Kazunori Kawaguchi, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Takamura, Tetsuo Ohta, Masao Honda, Shuichi Kaneko
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2020-01-01
Edice:	Cellular and Molecular Gastroenterology and Hepatology
Témata:	Hepatocellular Carcinoma Sorafenib Regorafenib Capicua
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352345X20300394
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!